Halozyme Therapeutics (HALO) Enterprise Value (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Enterprise Value of -$318.6 million for Q1 2026, up 57.4% year-over-year from -$202.4 million in Q1 2025, and down 123.09% quarter-over-quarter from -$142.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Enterprise Value (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Enterprise Value for 17 consecutive years, with -$318.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 57.4% year-over-year to -$318.6 million; the TTM figure through Mar 2026 stood at -$318.6 million (up 57.4% YoY), while the FY2025 annual figure was -$142.8 million, up 76.04% from the prior year.
- Enterprise Value fell to -$318.6 million in Q1 2026 per HALO's latest filing, from -$142.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$142.8 million in Q4 2025 and bottomed at -$786.1 million in Q1 2022.
- Historically, Enterprise Value has averaged -$457.7 million across 5 years, with a median of -$463.5 million in 2024.
- Annual changes were most pronounced in 2023 — Enterprise Value tumbled 81.97% — and 2025, when it jumped 76.04%.
- Halozyme Therapeutics' Enterprise Value stood at -$362.8 million in 2022, then climbed by 7.39% to -$336.0 million in 2023, then sank by 77.4% to -$596.1 million in 2024, then surged by 76.04% to -$142.8 million in 2025, then tumbled by 123.09% to -$318.6 million in 2026.
- Business Quant data shows HALO's Enterprise Value at -$318.6 million in Q1 2026, -$142.8 million in Q4 2025, and -$702.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | -231.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -231.00 Mn |
| Mar 31, 2026 | -318.62 Mn |
| Dec 31, 2025 | -142.82 Mn |
| Sep 30, 2025 | -701.96 Mn |
| Jun 30, 2025 | -548.18 Mn |
| Mar 31, 2025 | -747.92 Mn |
| Dec 31, 2024 | -596.07 Mn |
| Sep 30, 2024 | -666.31 Mn |
| Jun 30, 2024 | -529.03 Mn |
| Mar 31, 2024 | -463.45 Mn |
| Dec 31, 2023 | -336.00 Mn |
| Sep 30, 2023 | -483.28 Mn |
| Jun 30, 2023 | -348.28 Mn |
| Mar 31, 2023 | -275.61 Mn |
| Dec 31, 2022 | -362.79 Mn |
| Sep 30, 2022 | -265.58 Mn |
| Jun 30, 2022 | -209.36 Mn |
| Mar 31, 2022 | -786.14 Mn |
| Dec 31, 2021 | -740.92 Mn |
| Sep 30, 2021 | -815.92 Mn |